SBC Medical Group Holdings Announces Approval of Share Repurchase Program and Commencement of Share Repurchases
SBC Medical Group Holdings (NASDAQ: SBC) has announced a $5 million share repurchase program to be implemented from May 20, 2025, to May 20, 2026. The company believes its current share price undervalues its business performance and market potential. The repurchase will be funded through surplus cash and future free cash flow.
To fund this initiative, SBC will defer its previously announced Bitcoin purchase plan worth JPY 1 billion. The company plans to issue future stock-based compensation proportional to repurchased shares and is considering additional dividend distributions. Additionally, SBC is reviewing the potential acquisition of Risenet Co., Ltd., currently owned by CEO Yoshiyuki Aikawa, which provides management support to Rize Clinic and Gorilla Clinic.
SBC Medical Group Holdings (NASDAQ: SBC) ha annunciato un programma di riacquisto di azioni da 5 milioni di dollari, che sarà attuato dal 20 maggio 2025 al 20 maggio 2026. L'azienda ritiene che il prezzo attuale delle sue azioni non rifletta adeguatamente le sue performance operative e il potenziale di mercato. Il riacquisto sarà finanziato con liquidità in eccesso e flussi di cassa liberi futuri.
Per finanziare questa iniziativa, SBC rinvierà il piano precedentemente annunciato di acquisto di Bitcoin per un valore di 1 miliardo di JPY. L'azienda prevede di emettere compensi azionari futuri proporzionali alle azioni riacquistate e sta valutando la possibilità di distribuire dividendi aggiuntivi. Inoltre, SBC sta esaminando l'acquisizione potenziale di Risenet Co., Ltd., attualmente di proprietà del CEO Yoshiyuki Aikawa, che fornisce supporto gestionale a Rize Clinic e Gorilla Clinic.
SBC Medical Group Holdings (NASDAQ: SBC) ha anunciado un programa de recompra de acciones por 5 millones de dólares que se llevará a cabo desde el 20 de mayo de 2025 hasta el 20 de mayo de 2026. La compañía considera que el precio actual de sus acciones subestima su desempeño comercial y potencial de mercado. La recompra se financiará con efectivo excedente y flujo de caja libre futuro.
Para financiar esta iniciativa, SBC pospondrá su plan previamente anunciado de compra de Bitcoin por un valor de 1.000 millones de JPY. La empresa planea emitir compensaciones basadas en acciones proporcionales a las acciones recompradas y está considerando distribuciones adicionales de dividendos. Además, SBC está evaluando la posible adquisición de Risenet Co., Ltd., actualmente propiedad del CEO Yoshiyuki Aikawa, que brinda soporte administrativo a Rize Clinic y Gorilla Clinic.
SBC Medical Group Holdings (NASDAQ: SBC)는 2025년 5월 20일부터 2026년 5월 20일까지 시행될 500만 달러 규모의 자사주 매입 프로그램을 발표했습니다. 회사는 현재 주가가 자사의 사업 성과와 시장 잠재력을 저평가하고 있다고 판단하고 있습니다. 이번 자사주 매입은 잉여 현금과 미래의 자유 현금 흐름으로 자금을 조달할 예정입니다.
이 계획을 위해 SBC는 이전에 발표한 10억 엔 규모의 비트코인 구매 계획을 연기할 것입니다. 회사는 매입한 주식에 비례하는 향후 주식 기반 보상을 발행할 계획이며, 추가 배당금 지급도 검토 중입니다. 또한 SBC는 현재 CEO 요시유키 아이카와가 소유한 Risenet Co., Ltd.의 인수를 검토 중이며, 이 회사는 Rize Clinic과 Gorilla Clinic에 경영 지원을 제공하고 있습니다.
SBC Medical Group Holdings (NASDAQ : SBC) a annoncé un programme de rachat d'actions de 5 millions de dollars qui sera mis en œuvre du 20 mai 2025 au 20 mai 2026. La société estime que le cours actuel de ses actions sous-évalue ses performances commerciales et son potentiel de marché. Le rachat sera financé par des liquidités excédentaires et des flux de trésorerie disponibles futurs.
Pour financer cette initiative, SBC reportera son plan d'achat de Bitcoin précédemment annoncé, d'une valeur de 1 milliard de yens. La société prévoit d'émettre des rémunérations en actions futures proportionnelles aux actions rachetées et envisage des distributions de dividendes supplémentaires. De plus, SBC étudie l'acquisition potentielle de Risenet Co., Ltd., actuellement détenue par le PDG Yoshiyuki Aikawa, qui fournit un soutien à la gestion de Rize Clinic et Gorilla Clinic.
SBC Medical Group Holdings (NASDAQ: SBC) hat ein Aktienrückkaufprogramm im Wert von 5 Millionen US-Dollar angekündigt, das vom 20. Mai 2025 bis zum 20. Mai 2026 umgesetzt wird. Das Unternehmen ist der Ansicht, dass der aktuelle Aktienkurs die Geschäftsleistung und das Marktpotenzial unterschätzt. Der Rückkauf wird durch überschüssige liquide Mittel und zukünftige freie Cashflows finanziert.
Zur Finanzierung dieser Maßnahme wird SBC seinen zuvor angekündigten Bitcoin-Kaufplan im Wert von 1 Milliarde JPY aufschieben. Das Unternehmen plant, zukünftige aktienbasierte Vergütungen proportional zu den zurückgekauften Aktien auszugeben und erwägt zusätzliche Dividendenausschüttungen. Zudem prüft SBC die mögliche Übernahme von Risenet Co., Ltd., die derzeit im Besitz des CEO Yoshiyuki Aikawa ist und Managementunterstützung für die Rize Clinic und Gorilla Clinic bietet.
- Authorization of $5 million share repurchase program indicating confidence in company's value
- Company maintains strong cash position with surplus cash and future free cash flow to fund buyback
- Additional dividend distributions being considered to improve shareholder returns
- Potential acquisition of Risenet could maximize group synergies
- Plans to issue new shares for stock-based compensation may offset buyback benefits
- Deferral of previously announced Bitcoin purchase plan could signal change in strategic priorities
- Potential conflict of interest in Risenet acquisition as it's owned by the CEO
- Acquisition details including price and financial impact remain undetermined
Insights
SBC's $5M buyback signals management confidence while deferring Bitcoin purchases and exploring insider acquisition of service provider Risenet.
The $5 million share repurchase program SBC has announced is relatively modest but signals management's belief that the stock is undervalued relative to the company's growth prospects. This authorization represents clear confidence in the company's financial position, as it will be funded through surplus cash and future free cash flow.
Most notably, SBC is deferring its previously announced Bitcoin purchase plan (targeting JPY 1 billion or approximately $6.7 million) to allocate funds to this repurchase instead. This shift from cryptocurrency investment to share repurchases reflects a more conservative, shareholder-focused capital allocation strategy.
The company plans to issue new shares for stock-based compensation in proportion to repurchased shares, which effectively neutralizes the buyback's impact on share count but transfers value from cash to employees. This approach balances employee incentives with the buyback's anti-dilutive intent.
A significant development is the potential acquisition of Risenet, which provides management support to Rize and Gorilla Clinics. This would be an insider transaction as Risenet is wholly owned by SBC's CEO. With no details on pricing or structure, this related-party transaction warrants careful scrutiny for potential conflicts of interest.
The company's stated commitment to continued dividend distributions alongside the buyback program demonstrates a balanced approach to shareholder returns while still investing in growth opportunities within the aesthetic-medical market.
IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings (Nasdaq: SBC, “the Company”) today announces that its Board of Directors has approved the following share repurchase program and will commence repurchasing its own shares as early as May 20, 2025.
Share Repurchase Program
- Maximum aggregate amount: US
$5 million - Implementation period: May 20, 2025 – May 20, 2026
- Funding source: Surplus cash and future free cash flow
The Company believes its current share price undervalues its business performance, the growth potential of the aesthetic‑medical market, and its position as an industry leader. Based on this view, it has decided to purchase shares on the open market at prevailing market prices (including through Rule 10b5-1 plans) and the Company will continue to explore additional measures to enhance liquidity of its shares. The Company expects to issue shares as future stock‑based compensation in proportion to the number of repurchased shares.
To maximize shareholder value, the Company will pursue a balanced approach between growth investment and shareholder returns. In addition to the repurchase program, it will continue to consider dividend distributions with the goal of improving its total shareholder return.
To allocate funds to this repurchase, the Company has decided to defer further purchases under the Bitcoin purchase plan (targeting JPY 1 billion) announced on February 12, 2025.
Furthermore, to maximize group synergies, the Company has begun reviewing the acquisition of all shares of Risenet Co., Ltd. (“Risenet”) which provides management‑support services to Rize Clinic and Gorilla Clinic. All Risenet shares are currently held by the Company’s CEO, Yoshiyuki Aikawa. Details—including acquisition price, closing schedule, and impact on consolidated financials of the Company—have not yet been determined. The Company will disclose material information promptly as decisions are made.
About SBC Medical
SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchise clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchise clinic customers, assistance with franchise employee housing rentals and facility rentals, construction and design of franchise clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchise clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchise clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchise clinics.
For more information, visit https://sbc-holdings.com/
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s financial performance; growth in revenue and earnings; business prospects and opportunities; and capital deployment plans and liquidity. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
Contact:
In Asia:
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of Investor Relations
E-mail: ir@sbc-holdings.com
In the US:
ICR LLC
Bill Zima / Managing Partner
Email: bill.zima@icrinc.com
FAQ
What is the size and duration of SBC Medical Group's share repurchase program?
How will SBC Medical Group fund its share repurchase program?
What is SBC Medical Group's plan regarding Bitcoin purchases announced in February 2025?
What potential acquisition is SBC Medical Group considering?
How does SBC Medical Group plan to handle stock-based compensation?
